MRD business growth - MRD business revenue rose 33% yr/yr and made up 92% of total revenue
clonoSEQ test volume - clonoSEQ test volume increased 43% yr/yr to 36,111 tests delivered
Immune Medicine decline - Immune Medicine revenue fell 40% yr/yr, though excluding Genentech Agreement, revenue rose 8%
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $21.00, about 6.7% below its July 28 closing price of $22.52
Outlook and guidance
Adaptive Biotechnologies raises 2026 MRD revenue guidance to $268 mln-$278 mln
Company revises full-year operating expense guidance to $350 mln-$355 mln
No revenue guidance provided for Immune Medicine business
ADPT•
